Funding covers the evaluation of the company’s antigen-specific immunotherapeutic in rodent tumor models.
Juvaris BioTherapeutics was awarded a one-year Phase I SBIR grant from the NCI in collaboration with David Claxton, M.D., at Penn State College of Medicine to develop a therapeutic vaccine approach for acute myelogenous leukemia (AML). Juvaris’ vaccine technology will be tested in rodent tumor models to evaluate its impact using an antigen-specific immunotherapeutic AML vaccine (JuvaVax).

The SBIR grant application was supported by preclinical data generated by Juvaris and Dr. Claxton demonstrating significant protection in a rodent tumor model.

Previous articlePericor Science Finds Advance in Thrombin Inhibitor Research
Next articleKyowa Hakko Develops Production Method for L-Tyrosine Based on Fermentation